Abstract
Background and Aims : Liver X receptors (LXRa/β) are transcription factors that are key in the regulation of cholesterol homeostasis and inflammatory processes. LXR are a therapeutical target for cardiometabolic and neurodegenerative diseases, including Alzheimer’s disease (AD). AD is a progressive neurodegenerative disorder for which no effective therapy is available yet. We reported that activation of LXR by synthetic agonists restores cognitive decline in AD mice. Because of the hepatosteatosis and hypertriglyceridemia, induced by synthetic agonists, we are testing LXR-activating phytosterols that do not induce such side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
